Docetaxel Injection, Solution
Product Images NDC 0409-0016

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-0016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical structure diagram of Docetaxel anhydrous, showing the complex molecular arrangement with various rings, hydroxyl groups, and side chains typical of this active pharmaceutical ingredient used in injection solutions.*

FDA Label Image

Figure 1 (Docetaxel 02)

A line graph depicting Disease-Free Survival (DFS) Probability (%) over Disease-Free Survival Time in months for two treatment groups labeled TAC and FAC. The graph shows DFS probability decreasing over time from 0 to 66 months, with TAC generally showing a higher DFS probability compared to FAC.*

FDA Label Image

Figure 2 (Docetaxel 03)

A line graph showing survival probability (%) over survival time in months. Two groups are compared: TAC (solid line) and FAC (dashed line), with survival probabilities decreasing slightly over time from 0 to 66 months.*

FDA Label Image

Figure 3 (Docetaxel 04)

A Kaplan-Meier survival curve chart depicting cumulative probability of overall survival over time in months. It compares two groups, labeled T75 (solid line) and BSC (dashed line), showing survival probability decreasing over a period up to 21 months. A log-rank p-value of 0.010 is indicated, suggesting statistical comparison between groups.*

FDA Label Image

Figure 4 (Docetaxel 05)

A survival curve graph showing cumulative probability versus survival time in months. Two curves are labeled T75 (solid line) and V/I (dashed line), depicting overall survival with a log-rank p value of 0.13. The x-axis ranges from 0 to 21 months, and the y-axis ranges from 0 to 1.0 cumulative probability.*

FDA Label Image

Figure 5 (Docetaxel 06)

A Kaplan-Meier survival curve comparing two groups labeled T75 q3w and M q3w. The x-axis represents survival time in months from 0 to 30, and the y-axis shows survival probability from 0.0 to 1.0. The solid line (T75 q3w) shows higher survival probability over time compared to the dashed line (M q3w).*

FDA Label Image

Figure 6 (Docetaxel 07)

A Kaplan-Meier survival curve graph showing the probability in percentage on the Y-axis and time in months on the X-axis. Two treatment groups, TCF and CF, are compared with distinct survival probability trends over 24 months.*

FDA Label Image

Figure 7 (Docetaxel 08)

A Kaplan-Meier survival curve chart showing survival probability percentage over time in months up to 36 months. Two lines represent different treatment groups labeled TCF and CF, illustrating their respective survival probabilities decreasing over time.*

FDA Label Image

Figure 8 (Docetaxel 09)

A Kaplan-Meier survival curve displaying Progression-Free Survival (PFS) probability over time in months for two groups labeled TPF and PF. The y-axis represents PFS Probability (%) ranging from 0 to 100%, while the x-axis represents Progression Free Survival Time (months) from 0 to 42. The TPF group shows higher PFS probabilities compared to the PF group throughout the timeline.*

FDA Label Image

Figure 9 (Docetaxel 10)

A survival probability curve chart showing survival time in months on the x-axis and survival probability percentage on the y-axis. Two survival curves are displayed, labeled as TPF (solid line) and PF (dashed line), illustrating their survival probabilities over time up to 72 months.*

FDA Label Image

Figure 10 (Docetaxel 11)

A survival probability curve chart showing survival probability percentage on the vertical axis and survival time in months on the horizontal axis, comparing two groups labeled TPF and PF with respective patient counts. The chart includes a table below indicating the number of patients at risk over time for each group.*

FDA Label Image

Logo (Docetaxel 12)

FDA Label Image

Logo (Docetaxel 13)

FDA Label Image

Principal Display Panel (2 mL Vial Label)

Label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) solution for intravenous use. It is a 2 mL single-dose vial labeled as a cytotoxic agent. The label includes storage instructions (20°C to 25°C) and notes the product is distributed by Hospira, Inc. in Lake Forest, IL. Additional instructions mention checking concentration prior to preparation and discarding unused portions.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Box label for Docetaxel Injection, USP, 20 mg/2 mL (10 mg/mL) solution for intravenous use by Hospira, Inc. The box is marked as a single-dose vial, ready to add to infusion solution with dosage concentration and handling warnings. Includes the Novaplus logo and storage instructions at controlled room temperature.*

FDA Label Image

Principal Display Panel (16 mL Vial Label)

Label for Docetaxel Injection, USP, 160 mg/16 mL (10 mg/mL) intravenous solution, a multiple-dose vial for intravenous use only. The label includes concentration and preparation instructions, FDA-required cautions including "Cytotoxic Agent," storage conditions, and distributor information for Hospira, Inc. in Lake Forest, IL.*

FDA Label Image

Principal Display Panel (16 mL Vial Carton)

Packaging label for Docetaxel Injection USP 160 mg/16 mL (10 mg/mL) by Hospira, Inc. The label indicates the product is ready to add to infusion solution, intended for intravenous use only, and highlights the concentration and volume per vial. It includes cautionary notes about cytotoxicity, storage conditions, and a warning to keep out of reach of children. The label also features the Novaplus logo, the NDC number, and the distribution information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.